NCT03956680View on ClinicalTrials.gov

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

March 26, 2019

Primary Completion Date

April 17, 2024

Study Completion Date

April 24, 2024

Conditions
Advanced Solid Cancers
Interventions
DRUG

BMS-986301

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

BIOLOGICAL

Ipilimumab

Specified dose on specified days

Trial Locations (5)

37232

Local Institution - 0002, Nashville

60637

Local Institution - 0003, Chicago

63110

Local Institution - 0005, St Louis

15232-1305

Local Institution - 0006, Pittsburgh

M5G 1Z5

Local Institution - 0001, Toronto

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY